RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Researchers Created A Laser Bullet To See What It Would Look Like - And Here It Is
- Will Holding Thermal Printer Paper Really Send Your BPA Levels Soaring?
- The Quote Of The Week - Shocked And Disappointed
- As The Weather Changes, So Do Beliefs About Climate Change
- ECFA Workshop: Planning For The High Luminosity LHC
- Limiting Global Warming To 2°C: The Philosophy And The Science
- Great Earthquakes Doubled In The Most Recent 10 Year Period - What That Means
- "I have no time for you. Either learn how to have a decent, mature conversation without resorting..."
- "The past 12 months—October 2013–September 2014—was the warmest 12-month period among all..."
- "Do you really think science20 readers are all so stupid that they are going to fall for Climate..."
- "'Mememine' is a well known astro-turfer for the denial industry. He spams the same identical gish..."
- "I have heard (from someone who worked there) of a laboratory in a country far, far away where they..."
- National Wildlife Refuge System bans on GMOs and neonics lack transparency, scientific rationale
- Want better sperm? Eat more pesticides
- Beyond universal donors, some people are programed with no blood type at all
- Anti-conventional ag movement spurs Big Ag to look to organic pesticides
- Can people really inherit memories?
- An end to fat shaming? The 50 year DNA mystery of metabolic dysfunction may soon be solved
- New policymaking tool for shift to renewable energy
- Teens whose parents exert more psychological control have trouble with closeness, independence
- Two days later: Adolescents' conflicts with family spill over to school, vice versa
- Children in high-quality early childhood education are buffered from changes in family income
- 'Breath test' shows promise for diagnosing fungal pneumonia